Breast Cancer Res Treat (2018) 168:249–258 https://doi.org/10.1007/s10549-017-4514-z BRIEF REPORT Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer 1,2 3 4 5 • • • • Andrew Dodson David Okonji Laura Assersohn Anne Rigg 6 3 3 3 1,2 • • • • Amna Sheri Nick Turner Ian Smith Marina Parton Mitch Dowsett Received: 9 August 2017 / Accepted: 13 September 2017 / Published online: 11 November 2017 The Author(s) 2017. This article is an open access publication Abstract between RS%-derived categorical risk assignments and Purpose Oncotype DX, a gene expression assay widely treatment recommendation was evaluated. employed to aid decision making on adjuvant chemother- Results Data on 171 tests (168 patients) were available. apy use in patients with primary oestrogen receptor-posi- Median DR risk by RS% was 11% (range 3–34%), by tive (ER?) breast cancer, produces a recurrence score (RS) RSPC it was 15% (range 4–63%). Correlation between related to distant disease recurrence (DR) risk (RS%). In RS% and RSPC was 0.702 (p\ 0.001). RS% classiﬁed node-negative patients, RS can be integrated with clinico- 57.3% of cases as low-, 32.2% intermediate- and 10.5% pathological parameters to derive RS-pathology-clinical high-risk
Breast Cancer Research and Treatment – Springer Journals
Published: Nov 11, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud